Key facts
- RenaissThera’s last known valuation is $5.5M (Dec 2024).
- It has raised $500K; the latest was Angel (individual) ($500K) in Dec 2024.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for RenaissThera
- ·The full record, as it builds
Funding rounds
No funding rounds for RenaissThera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RenaissThera
Developer of novel small-molecule targeted therapies intended to enhance wellness through innovative therapeutic practices. The company leverages AI platforms focusing on high-unmet-need areas of prevalent diseases in key therapy areas such as cardio-metabolic including diabetes and obesity indications, enabling patients with affordable alternatives in relevant disease areas.
- Sector
- Healthcare
- HQ
- Bengaluru, India
- Founded
- 2023
- Employees
- 2
- Website
- renaissthera.com/
- Ownership
- Privately Held (backing)
RenaissThera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RenaissThera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RenaissThera in its N-PORT filings yet. We sweep new filings monthly.